Clinical Trial Update: Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated a tumor-derived immunoglobulin idiotype antigen vaccine for follicular lymphoma. The trial status indicates completion of the Phase 1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Follicular Lymphoma
• Lymphoma

Drugs mentioned

• Idiotype vaccine (tumor-derived immunoglobulin idiotype antigen vaccine) (tumor-derived immunoglobulin idiotype vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B Cell Lymphoma, Follicular Lymphoma | Phase 1 | Status: COMPLETED